Eugene Bauer - 16 Apr 2026 Form 4 Insider Report for Evommune, Inc. (EVMN)

Signature
/s/ Gregory S. Moss, Attorney-in-Fact
Issuer symbol
EVMN
Transactions as of
16 Apr 2026
Net transactions value
$0
Form type
4
Filing time
17 Apr 2026, 17:23:59 UTC
Previous filing
11 Dec 2025

Key filing fact

Eugene Bauer filed Form 4 for Evommune, Inc. (EVMN) on 17 Apr 2026.

Key facts

  • This page summarizes Eugene Bauer's Form 4 filing for Evommune, Inc. (EVMN).
  • 1 reported transaction and 1 derivative row are listed below.
  • Filing timestamp: 17 Apr 2026, 17:23.

Change

  • Previous filing in this sequence was filed on 11 Dec 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

CIK 0001678620 Primary reporting owner

Bauer Eugene

Relationship
Chief Medical Officer, Director
Address
C/O EVOMMUNE, INC., 1891 PAGE MILL ROAD, PALO ALTO
Signature
/s/ Gregory S. Moss, Attorney-in-Fact
Signature date
17 Apr 2026

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

EVMN transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value
Shares
+51,117
Change %
Price
$0.000000*
Shares after
51,117
Date
16 Apr 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
51,117
Exercise price
$26.77
Footnotes
F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .